Upadacitinib Is Safe and Effective for Crohn's Disease : Real-World Data from a Tertiary Center
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Upadacitinib is a selective JAK-1 inhibitor approved for the treatment of rheumatoid arthritis and more recently, ulcerative colitis. Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease. However, real-world data are lacking. We present a short report on our experience with off-label upadacitinib in patients with CD at a tertiary center. In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively. Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
---|---|
Enthalten in: |
Digestive diseases and sciences - 68(2023), 2 vom: 13. Feb., Seite 385-388 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Traboulsi, Cindy [VerfasserIn] |
---|
Links: |
---|
Themen: |
4RA0KN46E0 |
---|
Anmerkungen: |
Date Completed 09.02.2023 Date Revised 21.03.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10620-022-07582-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM342175963 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM342175963 | ||
003 | DE-627 | ||
005 | 20231226013507.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10620-022-07582-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1140.xml |
035 | |a (DE-627)NLM342175963 | ||
035 | |a (NLM)35695972 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Traboulsi, Cindy |e verfasserin |4 aut | |
245 | 1 | 0 | |a Upadacitinib Is Safe and Effective for Crohn's Disease |b Real-World Data from a Tertiary Center |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.02.2023 | ||
500 | |a Date Revised 21.03.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
520 | |a Upadacitinib is a selective JAK-1 inhibitor approved for the treatment of rheumatoid arthritis and more recently, ulcerative colitis. Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease. However, real-world data are lacking. We present a short report on our experience with off-label upadacitinib in patients with CD at a tertiary center. In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively. Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Crohn’s disease | |
650 | 4 | |a Inflammatory bowel disease | |
650 | 4 | |a Upadacitinib | |
650 | 7 | |a upadacitinib |2 NLM | |
650 | 7 | |a 4RA0KN46E0 |2 NLM | |
650 | 7 | |a Heterocyclic Compounds, 3-Ring |2 NLM | |
700 | 1 | |a Ayoub, Fares |e verfasserin |4 aut | |
700 | 1 | |a Silfen, Alexa |e verfasserin |4 aut | |
700 | 1 | |a Rodriguez, Tina G |e verfasserin |4 aut | |
700 | 1 | |a Rubin, David T |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d 1989 |g 68(2023), 2 vom: 13. Feb., Seite 385-388 |w (DE-627)NLM000356492 |x 1573-2568 |7 nnns |
773 | 1 | 8 | |g volume:68 |g year:2023 |g number:2 |g day:13 |g month:02 |g pages:385-388 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10620-022-07582-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 68 |j 2023 |e 2 |b 13 |c 02 |h 385-388 |